Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

9.1%

3 terminated/withdrawn out of 33 trials

Success Rate

72.7%

-13.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

11 recruiting

Enrollment Performance

Analytics

Phase 2
15(51.7%)
N/A
14(48.3%)
29Total
Phase 2(15)
N/A(14)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (33)

Showing 20 of 33 trials
NCT07285356Not ApplicableRecruiting

Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy

Role: lead

NCT07268846Not ApplicableRecruiting

Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery

Role: lead

NCT05592938Not ApplicableRecruiting

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

Role: collaborator

NCT07167329Phase 2Recruiting

Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

Role: collaborator

NCT06328751Not ApplicableRecruiting

Meditation With Virtual Reality for Cancer Pain Relief in the Pain Therapy and Palliative Care Service

Role: collaborator

NCT06793137Phase 2Recruiting

Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Role: lead

NCT06215027Not ApplicableRecruiting

The Effects of Dance for Breast Cancer Patients Undergoing Surgical Treatment

Role: lead

NCT03366051Not ApplicableRecruiting

Sentinel Node Mapping in High Risk Endometrial Cancer

Role: lead

NCT06472388Phase 2Recruiting

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Role: lead

NCT03870399Phase 2Completed

Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

Role: lead

NCT06207487Unknown

Evaluation of Herpes Zoster Characteristics and Costs in Cancer Population.

Role: lead

NCT03789149Phase 2Terminated

Focal Intraoperative Radiotherapy of Brain Metastases

Role: lead

NCT03512899Not ApplicableCompleted

Comparison Between Internal Jugular Vein Versus Axillary Vein for Implantable Ports

Role: lead

NCT05242991Not ApplicableUnknown

Effectiveness of Photobiomodulation Protocols in Radiation-induced Oral Side Effects in H&N Cancer Patients

Role: collaborator

NCT05759975Not ApplicableUnknown

Effectiveness of Extraoral Photobiomodulation in Management of Oral Adverse Effects in Patients Undergoing HSCT

Role: collaborator

NCT04168931Phase 2Terminated

Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC

Role: lead

NCT03870607Phase 2Unknown

Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT)

Role: lead

NCT01925651Not ApplicableCompleted

Clinical Trial of The Use of Bolus in Post Mastectomy Irradiation in Breast Cancer

Role: lead

NCT04831567Phase 2Withdrawn

Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors

Role: lead

NCT05084040Phase 2Unknown

Non-inferiority of Clinical Trials in Comparison With the Length of Totally Implemented Porth-a-Cath Maintenance From 60 Versus 90 Days

Role: lead